{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:09:27Z","timestamp":1790168967241,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014091","name":"AstraZeneca Pharma Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.hfc.2021.06.001","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T03:47:28Z","timestamp":1626925648000},"page":"519-531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pathophysiology of Advanced Heart Failure"],"prefix":"10.1016","volume":"17","author":[{"given":"Jan","family":"Biegus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Niewinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystian","family":"Josiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kulej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ponikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zymlinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.hfc.2021.06.001_bib1","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.hfc.2021.06.001_bib2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.hfc.2021.06.001_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel","volume":"76","author":"Wilcox","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2021.06.001_bib4","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cardiores.2006.01.013","article-title":"Autonomic imbalance and immune activation in chronic heart failure \u2014Pathophysiological links","volume":"70","author":"Jankowska","year":"2006","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.hfc.2021.06.001_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nri3800","article-title":"Role of innate and adaptive immune mechanisms in cardiac injury and repair","volume":"15","author":"Epelman","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.hfc.2021.06.001_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.hfc.2021.06.001_bib7","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/eurheartj\/ehv087","article-title":"The sympathetic\/parasympathetic imbalance in heart failure with reduced ejection fraction","volume":"36","author":"Floras","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2021.06.001_bib8","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/01.CIR.85.4.1374","article-title":"Plasma endothelin in chronic heart failure","volume":"85","author":"McMurray","year":"1992","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2021.06.001_bib9","first-page":"49","article-title":"Arginine vasopressin antagonism in heart failure: Current status and possible new directions","volume":"74","author":"Goldsmith","year":"2019","journal-title":"J\u00a0Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2021.06.001_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","article-title":"Reappraising the role of inflammation in heart failure","volume":"17","author":"Adamo","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"27","key":"10.1016\/j.hfc.2021.06.001_bib11","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.hfc.2021.06.001_bib12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF","volume":"8","author":"Docherty","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2021.06.001_bib13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.hfc.2021.06.001_bib14","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3390\/ijms20133198","article-title":"Endothelial Dysfunction in Chronic Heart Failure: Assessment, Findings, Significance, and Potential Therapeutic Targets","volume":"20","author":"Alem","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hfc.2021.06.001_bib15","series-title":"Endothelin in renal physiology and disease","first-page":"76","article-title":"Role of endothelin in thick ascending limb sodium chloride transport","author":"Ramseyer","year":"2011"},{"key":"10.1016\/j.hfc.2021.06.001_bib16","first-page":"317","article-title":"Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials","volume":"5","author":"Packer","year":"2017","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.hfc.2021.06.001_bib17","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: The VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2021.06.001_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10741-012-9323-1","article-title":"Soluble guanylate cyclase: a potential therapeutic target for heart failure","volume":"18","author":"Gheorghiade","year":"2013","journal-title":"Heart Fail Rev"},{"issue":"15","key":"10.1016\/j.hfc.2021.06.001_bib19","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","article-title":"Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week","volume":"76","author":"Emdin","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2021.06.001_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11897-018-0383-y","article-title":"Multiple avenues of modulating the nitric oxide pathway in heart failure clinical trials","volume":"15","author":"Singh","year":"2018","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.hfc.2021.06.001_bib21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2021.06.001_bib22","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hfc.2021.06.001_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/euhj.1998.1446","article-title":"Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure","volume":"20","author":"Anker","year":"1999","journal-title":"Eur Heart J"},{"issue":"2\u20133","key":"10.1016\/j.hfc.2021.06.001_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-5273(02)00470-9","article-title":"How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH","volume":"86","author":"Anker","year":"2002","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.06.001_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ejhf.1306","article-title":"Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mild-to-moderate heart failure with reduced ejection fraction: a retrospective analysis of 5-year survival","volume":"21","author":"Paleczny","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.hfc.2021.06.001_bib26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2008.09.034","article-title":"Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era","volume":"53","author":"La Rovere","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.06.001_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2020.05.015","article-title":"Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction","volume":"76","author":"Zile","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.06.001_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jacc.2016.03.525","article-title":"Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial","volume":"68","author":"Gold","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.hfc.2021.06.001_bib29","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.cardfail.2013.03.013","article-title":"Clinical predictors and hemodynamic consequences of elevated peripheral chemosensitivity in optimally treated men with chronic systolic heart failure","volume":"19","author":"Niewinski","year":"2013","journal-title":"J\u00a0Card Fail"},{"issue":"5","key":"10.1016\/j.hfc.2021.06.001_bib30","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/hc3101.093699","article-title":"Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure","volume":"104","author":"Ponikowski","year":"2001","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2021.06.001_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.resp.2008.12.002","article-title":"Role of chemoreceptors in mediating dyspnea","volume":"167","author":"Buchanan","year":"2009","journal-title":"Respir Physiol Neurobiol"},{"issue":"6","key":"10.1016\/j.hfc.2021.06.001_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/hrt.76.6.483","article-title":"Contribution of peripheral chemoreceptors to ventilation and the effects of their suppression on exercise tolerance in chronic heart failure","volume":"76","author":"Chua","year":"1996","journal-title":"Heart"},{"issue":"25","key":"10.1016\/j.hfc.2021.06.001_bib33","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.jacc.2013.07.079","article-title":"Carotid chemoreceptor ablation improves survival in heart failure: rescuing autonomic control of cardiorespiratory function","volume":"62","author":"Del Rio","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.06.001_bib34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ejhf.641","article-title":"Carotid body resection for sympathetic modulation in systolic heart failure: results from first-in-man study","volume":"19","author":"Niewinski","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.06.001_bib35","first-page":"JP281319","article-title":"Oxygenation pattern and compensatory responses to hypoxia and hypercapnia following bilateral carotid body resection in humans","author":"Niewinski","year":"2021","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.hfc.2021.06.001_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-94-007-4584-1_46","article-title":"Role of central\/peripheral chemoreceptors and their interdependence in the pathophysiology of sleep apnea","volume":"758","author":"Dempsey","year":"2012","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"10.1016\/j.hfc.2021.06.001_bib37","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ejhf.1312","article-title":"Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure","volume":"20","author":"Costanzo","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.06.001_bib38","article-title":"Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial","author":"Giannoni","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"10.1016\/j.hfc.2021.06.001_bib39","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1161\/hc4401.098491","article-title":"Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure","volume":"104","author":"Ponikowski","year":"2001","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.hfc.2021.06.001_bib40","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1113\/JP280333","article-title":"Locomotor muscle group III\/IV afferents constrain stroke volume and contribute to exercise intolerance in human heart failure","volume":"598","author":"Smith","year":"2020","journal-title":"J\u00a0Physiol"},{"issue":"5","key":"10.1016\/j.hfc.2021.06.001_bib41","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1161\/01.CIR.93.5.940","article-title":"Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: Effects of physical training","volume":"93","author":"Piepoli","year":"1996","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hfc.2021.06.001_bib42","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1152\/jappl.1994.76.4.1575","article-title":"Training partially reverses skeletal muscle metabolic abnormalities during exercise in heart failure","volume":"76","author":"Stratton","year":"1994","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.hfc.2021.06.001_bib43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM199908193410806","article-title":"Hormones and hemodynamics in heart failure","volume":"341","author":"Schrier","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hfc.2021.06.001_bib44","doi-asserted-by":"crossref","first-page":"e002922","DOI":"10.1161\/CIRCHEARTFAILURE.115.002922","article-title":"Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed","volume":"9","author":"Miller","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hfc.2021.06.001_bib45","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehx035","article-title":"Renal sodium avidity in heart failure: from pathophysiology to treatment strategies","volume":"38","author":"Mullens","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2021.06.001_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1753","article-title":"Clinical importance of urinary sodium excretion in acute heart failure","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.06.001_bib47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ejhf.1428","article-title":"Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure","volume":"21","author":"Biegus","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.06.001_bib48","article-title":"Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients","author":"Biegus","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.hfc.2021.06.001_bib49","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41569-020-0379-7","article-title":"Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment","volume":"17","author":"Boorsma","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"10.1016\/j.hfc.2021.06.001_bib50","doi-asserted-by":"crossref","first-page":"e004763","DOI":"10.1161\/CIRCHEARTFAILURE.117.004763","article-title":"Dermal Interstitial Alterations in Patients With Heart Failure and Reduced Ejection Fraction: A Potential Contributor to Fluid Accumulation?","volume":"11","author":"Nijst","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"44","key":"10.1016\/j.hfc.2021.06.001_bib51","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1093\/eurheartj\/ehy600","article-title":"Treatments targeting inotropy","volume":"40","author":"Maack","year":"2019","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.hfc.2021.06.001_bib52","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jacc.2019.02.051","article-title":"Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week","volume":"73","author":"Psotka","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2021.06.001_bib53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF","volume":"8","author":"Teerlink","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.hfc.2021.06.001_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hfc.2021.06.001_bib55","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ejhf.570","article-title":"A\u00a0Gordian knot: disentangling comorbidities in heart failure","volume":"18","author":"Luo","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"10.1016\/j.hfc.2021.06.001_bib56","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.hfc.2021.06.001_bib57","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ejhf.600","article-title":"Reframing the association and significance of co-morbidities in heart failure","volume":"18","author":"Triposkiadis","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hfc.2021.06.001_bib58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A\u00a0novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2021.06.001_bib59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10741-018-9685-0","article-title":"The heart failure burden of type 2 diabetes mellitus \u2013 a review of pathophysiology and interventions","volume":"23","author":"Ofstad","year":"2018","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.hfc.2021.06.001_bib60","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hfc.2021.06.001_bib61","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.yjmcc.2012.11.019","article-title":"Structural and functional insights into the cardiac Na\/H exchanger","volume":"61","author":"Lee","year":"2013","journal-title":"J\u00a0Moll Cell Cardiol"},{"key":"10.1016\/j.hfc.2021.06.001_bib62","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2021.06.001_bib63","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.06.001_bib64","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"373","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.06.001_bib65","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.hfc.2021.06.001_bib66","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.06.001_bib67","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors. JACC state-of-the-art. Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.06.001_bib68","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jacbts.2019.08.009","article-title":"Iron and Heart Failure: Diagnosis, Therapies, and Future Directions","volume":"5","author":"Ghafourian","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.hfc.2021.06.001_bib69","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1093\/eurheartj\/ehu235","article-title":"Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure","volume":"35","author":"Jankowska","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2021.06.001_bib70","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","article-title":"Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2021.06.001_bib71","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart \u2013 an engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.06.001_bib72","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5603\/KP.a2019.0014","article-title":"Elevated lactate in acute heart failure patients with intracellular iron deficiency as identifier of poor outcome","volume":"77","author":"Biegus","year":"2019","journal-title":"Kard Pol"},{"key":"10.1016\/j.hfc.2021.06.001_bib73","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2021.06.001_bib74","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"issue":"10266","key":"10.1016\/j.hfc.2021.06.001_bib75","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.hfc.2021.06.001_bib76","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/eurheartj\/ehp507","article-title":"Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative","volume":"31","author":"Ronco","year":"2010","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.hfc.2021.06.001_bib77","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.hfc.2021.06.001_bib78","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.hfc.2021.06.001_bib79","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ejhf.1378","article-title":"Multi-organ dysfunction\/injury on admission identifies acute heart failure patients at high risk of poor outcome","volume":"21","author":"Zymli\u0144ski","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.hfc.2021.06.001_bib80","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/ehf2.12477","article-title":"Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial","volume":"6","author":"Biegus","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hfc.2021.06.001_bib81","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/ejhf.644","article-title":"Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure","volume":"18","author":"Biegus","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.06.001_bib82","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ejhf.532","article-title":"Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study","volume":"18","author":"Biegus","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.06.001_bib83","doi-asserted-by":"crossref","first-page":"471","DOI":"10.20452\/pamw.1413","article-title":"Liver function tests in patients with acute heart failure","volume":"122","author":"Biegus","year":"2012","journal-title":"Pol Arch Intern Med"},{"issue":"5","key":"10.1016\/j.hfc.2021.06.001_bib84","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvz035","article-title":"Common risk factors for heart failure and cancer","volume":"115","author":"Meijers","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.hfc.2021.06.001_bib85","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.hfc.2021.06.001_bib86","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1161\/CIRCULATIONAHA.118.033603","article-title":"Linking Heart Failure to Cancer: Background Evidence and Research Perspectives","volume":"138","author":"Bertero","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.hfc.2021.06.001_bib87","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jacc.2013.04.088","article-title":"Patients with heart failure have an increased risk of incident cancer","volume":"62","author":"Hasin","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2021.06.001_bib88","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jacc.2018.01.069","article-title":"Lack of association between heart failure and incident cancer","volume":"71","author":"Selvaraj","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.hfc.2021.06.001_bib89","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrcardio.2017.51","article-title":"Muscle wasting and cachexia in heart failure: mechanisms and therapies","volume":"14","author":"von Haehling","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2021.06.001_bib90","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jcsm.12483","article-title":"Sarcopenia: A Time for Action. An SCWD Position Paper","volume":"10","author":"Bauer","year":"2019","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:42:51Z","timestamp":1761554571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713621000672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1551713621000672"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2021.06.001","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology of Advanced Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2021.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}